CING - Cingulate Inc.
IEX Last Trade
4.76
0 0%
Share volume: 200
Last Updated: Thu 26 Dec 2024 08:10:24 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$4.76
0.00
0.00%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
2.10%
1 Month
11.47%
3 Months
-5.45%
6 Months
767.86%
1 Year
145.45%
2 Year
-74.57%
Key data
Stock price
$4.76
DAY RANGE
$4.76 - $4.82
52 WEEK RANGE
$0.27 - $20.83
52 WEEK CHANGE
-$50.51
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Shane J. Schaffer
Region: US
Website: cingulate.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cingulate.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Cingulate Inc. focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
Recent news